<DOC>
	<DOCNO>NCT02596958</DOCNO>
	<brief_summary>The purpose non-interventional study collection documentation data safety efficacy intravenous ( IV ) bevacizumab ( Avastin ) addition platinum-based chemotherapy first-line treatment participant unresectable advanced , metastatic recurrent non-small cell lung cancer ( NSCLC ) predominantly squamous cell histology focus adenocarcinoma elderly patient daily routine .</brief_summary>
	<brief_title>Safety Efficacy Study Avastin Locally Advanced Metastatic Recurrent Non-small Lung Cancer ( NSLC ) Participants</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age great equal ( &gt; = ) 18 year Histologically confirm predominantly nonsquamous NSCLC unresectably advance , metastatic recurrent ( without adenocarcinoma ) No contraindication Avastin® accord current Summary Product Characteristics ( SmPC ) Avastin® Therapeutic decision Avastin® first line treatment combination platinumbased chemotherapy take individually independent noninterventional trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>